The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab.
 
Hanneke Kievit
Research Funding - Roche (Inst)
 
M Benthe Muntinghe-Wagenaar
No Relationships to Disclose
 
Fred Ubbels
No Relationships to Disclose
 
Robin Wijsman
No Relationships to Disclose
 
Lucie Hijmering-Kappelle
No Relationships to Disclose
 
Birgitta Hiddinga
No Relationships to Disclose
 
Harry J.M. Groen
Consulting or Advisory Role - AstraZeneca (Inst); Lilly; Novartis (Inst); Roche/Genentech (Inst)
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Huib A.M. Kerstjens
Consulting or Advisory Role - Chiesi (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
 
Anthonie J. van der Wekken
Honoraria - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
Consulting or Advisory Role - AZD (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Janssen (Inst); Novartis (Inst); Takeda (Inst)
Research Funding - AZD (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
T.Jeroen Jeroen Nicolaas Hiltermann
Consulting or Advisory Role - AZD (Inst); BMS (Inst); MSD (Inst); Roche (Inst)
Research Funding - AZD (Inst); BMS (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst)